Delayed postprandial TAG peak after intake of SFA compared with PUFA in subjects with and without familial hypercholesterolaemia: a randomised controlled trial

Br J Nutr. 2018 May;119(10):1142-1150. doi: 10.1017/S0007114518000673.

Abstract

Postprandial hypertriacylglycerolaemia is associated with an increased risk of developing CVD. How fat quality influences postprandial lipid response is scarcely explored in subjects with familial hypercholesterolaemia (FH). The aim of this study was to investigate the postprandial response of TAG and lipid sub-classes after consumption of high-fat meals with different fat quality in subjects with FH compared with normolipidaemic controls. A randomised controlled double-blind cross-over study with two meals and two groups was performed. A total of thirteen hypercholesterolaemic subjects with FH who discontinued lipid-lowering treatment 4 weeks before and during the study, and fourteen normolipidaemic controls, were included. Subjects were aged 18-30 years and had a BMI of 18·5-30·0 kg/m2. Each meal consisted of a muffin containing 60 g (70 E%) of fat, either mainly SFA (40 E%) or PUFA (40 E%), eaten in a random order with a wash-out period of 3-5 weeks between the meals. Blood samples were collected at baseline (fasting) and 2, 4 and 6 h after intake of the meals. In both FH and control subjects, the level of TAG and the largest VLDL sub-classes peaked at 2 h after intake of PUFA and at 4 h after intake of SFA. No significant differences were found in TAG levels between meals or between groups (0·25≤P≤0·72). The distinct TAG peaks may reflect differences in the postprandial lipid metabolism after intake of fatty acids with different chain lengths and degrees of saturation. The clinical impact of these findings remains to be determined.

Keywords: CM chylomicrons; FH familial hypercholesterolaemia; PCSK9 proprotein convertase subtilisin/kexin type 9; iAUC incremental AUC; Familial hypercholesterolaemia; Lipoprotein sub-classes; Postprandial metabolism; Proprotein convertase subtilisin/kexin type 9; TAG; apoB48.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Area Under Curve
  • Body Mass Index
  • Cross-Over Studies
  • Diet, High-Fat / adverse effects*
  • Double-Blind Method
  • Fatty Acids / administration & dosage*
  • Fatty Acids, Unsaturated / administration & dosage*
  • Female
  • Humans
  • Hyperlipoproteinemia Type II / blood*
  • Lipoproteins, VLDL / blood
  • Male
  • Postprandial Period / physiology*
  • Time Factors
  • Triglycerides / blood*

Substances

  • Fatty Acids
  • Fatty Acids, Unsaturated
  • Lipoproteins, VLDL
  • Triglycerides